Continue to site >
Trending ETFs

Name

As of 06/21/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$18.23

$1.8 B

0.00%

1.98%

Vitals

YTD Return

10.6%

1 yr return

15.9%

3 Yr Avg Return

3.0%

5 Yr Avg Return

10.5%

Net Assets

$1.8 B

Holdings in Top 10

51.7%

52 WEEK LOW AND HIGH

$18.2
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 1.98%

SALES FEES

Front Load N/A

Deferred Load 1.00%

TRADING FEES

Turnover 77.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$1,000

IRA

$1,000


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 06/21/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$18.23

$1.8 B

0.00%

1.98%

PHLCX - Profile

Distributions

  • YTD Total Return 10.6%
  • 3 Yr Annualized Total Return 3.0%
  • 5 Yr Annualized Total Return 10.5%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.47%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    PGIM Jennison Health Sciences Fund
  • Fund Family Name
    Prudential
  • Inception Date
    Jul 12, 1999
  • Shares Outstanding
    N/A
  • Share Class
    C
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    David Chan

Fund Description

The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (“HMOs”) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The group of industries in which the Fund concentrates its investments is known as its “sector”. The term “investable assets” refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions.The Fund invests in securities of issuers among a number of different countries throughout the world, one of which is the United States. The Fund has no limit on the amount of assets that must be invested in each country. However, the Fund’s investments in the securities of non-U.S. issuers, which are referred to as “foreign securities” and includes stocks and other equity-related securities, is limited to 35% of the Fund's total assets.The Fund participates in the initial public offering (“IPO”) market.Equity and equity-related securities in which the Fund primarily invests are common stocks, nonconvertible preferred stocks and convertible securities. The Fund holds those equity and equity-related securities in which the portfolio managers have a high level of conviction for outperformance in the intermediate and long term and believe have limited downside potential in the short term. The portfolio managers use fundamental and quantitative analyses to select individual securities.The subadviser considers selling or reducing a stock position when, in the opinion of the subadviser, the stock has experienced a fundamental disappointment in earnings; the stock has experienced adverse price movement; the stock has reached an intermediate-term price objective and its outlook no longer seems sufficiently promising; or a relatively more attractive stock emerges.
Read More

PHLCX - Performance

Return Ranking - Trailing

Period PHLCX Return Category Return Low Category Return High Rank in Category (%)
YTD 10.6% -25.9% 26.5% 11.73%
1 Yr 15.9% -28.0% 31.5% 15.43%
3 Yr 3.0%* -34.6% 13.4% 33.55%
5 Yr 10.5%* -7.0% 16.7% 16.67%
10 Yr 9.8%* -0.6% 13.3% 23.36%

* Annualized

Return Ranking - Calendar

Period PHLCX Return Category Return Low Category Return High Rank in Category (%)
2023 -0.7% -12.6% 19.0% 72.84%
2022 -14.3% -53.9% 3.2% 69.03%
2021 -39.6% -39.6% 24.2% 100.00%
2020 2.6% -13.6% 178.2% 90.07%
2019 12.3% 3.8% 63.8% 91.85%

Total Return Ranking - Trailing

Period PHLCX Return Category Return Low Category Return High Rank in Category (%)
YTD 10.6% -25.9% 26.5% 11.73%
1 Yr 15.9% -28.0% 31.5% 15.43%
3 Yr 3.0%* -34.6% 13.4% 33.55%
5 Yr 10.5%* -7.0% 16.7% 16.67%
10 Yr 9.8%* -0.6% 13.3% 23.36%

* Annualized

Total Return Ranking - Calendar

Period PHLCX Return Category Return Low Category Return High Rank in Category (%)
2023 11.4% -12.6% 19.0% 11.11%
2022 -11.1% -53.9% 3.7% 43.87%
2021 5.2% -33.9% 26.0% 69.68%
2020 40.2% -0.7% 180.6% 12.58%
2019 17.4% 4.6% 63.8% 97.04%

NAV & Total Return History


PHLCX - Holdings

Concentration Analysis

PHLCX Category Low Category High PHLCX % Rank
Net Assets 1.8 B 7.41 M 47.2 B 24.69%
Number of Holdings 59 25 420 79.01%
Net Assets in Top 10 932 M 2.19 M 22.7 B 30.86%
Weighting of Top 10 51.75% 17.8% 78.7% 31.48%

Top 10 Holdings

  1. Eli Lilly Co 11.54%
  2. Merck Co Inc 7.44%
  3. AbbVie Inc 6.55%
  4. UnitedHealth Group Inc 4.45%
  5. Vertex Pharmaceuticals Inc 4.35%
  6. Novo Nordisk A/S 4.11%
  7. Apellis Pharmaceuticals Inc 3.97%
  8. Cigna Group/The 3.27%
  9. Becton Dickinson Co 3.08%
  10. Boston Scientific Corp 2.99%

Asset Allocation

Weighting Return Low Return High PHLCX % Rank
Stocks
98.37% 89.34% 106.13% 53.09%
Cash
3.93% 0.00% 34.44% 32.72%
Preferred Stocks
0.00% 0.00% 7.86% 96.30%
Other
0.00% -22.99% 23.31% 91.36%
Convertible Bonds
0.00% 0.00% 0.37% 94.27%
Bonds
0.00% 0.00% 12.39% 95.06%

Stock Sector Breakdown

Weighting Return Low Return High PHLCX % Rank
Healthcare
100.00% 59.26% 100.00% 45.22%
Utilities
0.00% 0.00% 0.00% 93.63%
Technology
0.00% 0.00% 22.69% 94.27%
Real Estate
0.00% 0.00% 5.89% 93.63%
Industrials
0.00% 0.00% 7.02% 94.27%
Financial Services
0.00% 0.00% 1.60% 97.45%
Energy
0.00% 0.00% 0.00% 93.63%
Communication Services
0.00% 0.00% 9.11% 95.54%
Consumer Defense
0.00% 0.00% 25.73% 94.27%
Consumer Cyclical
0.00% 0.00% 1.92% 93.63%
Basic Materials
0.00% 0.00% 7.16% 96.82%

Stock Geographic Breakdown

Weighting Return Low Return High PHLCX % Rank
US
96.91% 69.36% 104.41% 36.42%
Non US
1.47% 0.00% 27.72% 55.56%

PHLCX - Expenses

Operational Fees

PHLCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.98% 0.08% 4.28% 17.90%
Management Fee 0.73% 0.03% 1.25% 59.88%
12b-1 Fee 1.00% 0.00% 1.00% 100.00%
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

PHLCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load 1.00% 1.00% 5.00% 100.00%

Trading Fees

PHLCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHLCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 77.00% 0.00% 238.00% 93.48%

PHLCX - Distributions

Dividend Yield Analysis

PHLCX Category Low Category High PHLCX % Rank
Dividend Yield 0.00% 0.00% 6.24% 98.15%

Dividend Distribution Analysis

PHLCX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual Annual Annual

Net Income Ratio Analysis

PHLCX Category Low Category High PHLCX % Rank
Net Income Ratio -1.47% -2.54% 1.85% 96.13%

Capital Gain Distribution Analysis

PHLCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

PHLCX - Fund Manager Analysis

Managers

David Chan


Start Date

Tenure

Tenure Rank

Jun 30, 1999

22.93

22.9%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.

Debra Netschert


Start Date

Tenure

Tenure Rank

Jan 28, 2015

7.34

7.3%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.

Daniel Matviyenko


Start Date

Tenure

Tenure Rank

Dec 15, 2020

1.46

1.5%

Daniel joined Jennison in December 2020 as a Managing Director and co-Portfolio Manager of Health Sciences strategies. Before joining Jennison, he was founder, chief investment officer, and portfolio manager at Malleus Capital. Prior to founding Malleus, Dan was a portfolio manager, managing director, and partner at Tudor Investment. Before joining Tudor, he was a portfolio manager and an executive director at UBS O’Connor. Earlier in his career, Dan held various roles as an equity analyst at a number of firms. Dan holds a BS in finance from the University of Connecticut.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.87 0.25